Concepedia

Scott A. Biller

SA

65

Publications

10K

Citations

43

H-Index

1975

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Agios Pharmaceuticals (United States)

Bristol-Myers Squibb (Germany)

Institut Gustave Roussy

Memorial Sloan Kettering Cancer Center

Scott A. Biller is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and biochemistry.

Top concepts

Publications per year

1975–2022

65

Publications

65

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

Dan Rohle, Janeta Popovici-Müller, Nicolaos Palaskas et al. · Science · 2013 · 1.1K citations · Full text

, , +16

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Jeremy Travins, Byron DeLaBarre et al. · Science · 2013 · 789 citations

Electrophilic properties of itaconate and derivatives regulate the IκBζ–ATF3 inflammatory axis

Monika Bambousková, Laurent Gorvel, Vicky Lampropoulou et al. · Nature · 2018 · 695 citations · Full text

, , +12

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 617 citations · Full text

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl et al. · Journal of Medicinal Chemistry · 2008 · 612 citations · Full text

, , +10

Rows per page

1–5 of 65